Nano Biotechnology Market Research Report: Information By Application (Pharmaceuticals, Medical Devise, Medical Research, Food and Agriculture), By Therapeutics (Dental Therapies, Cardiac Therapies, Orthopedic Therapies and Others) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Product

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL NANO BIOTECHNOLOGYMARKET, BY APPLICATION

6.1. Overview

6.2. Pharmaceuticals

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.3. Medical Devices

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.4. Medical Research

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

6.5. Food and Agriculture

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7. GLOBAL NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS

7.1. Overview

7.2. Dental Therapies

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.3. Cardiac Therapies

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.4. Orthopedic Therapies

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

7.5. Others

Market Estimates & Forecast, by Region, 2022–2030

Market Estimates & Forecast, by Country, 2022–2030

8. GLOBAL NANO BIOTECHNOLOGYMARKET, BY REGION

8.1. Overview

8.2. North America

8.2.1. US

8.2.2. Canada

8.3. Europe

8.3.1. Germany

8.3.2. France

8.3.3. Italy

8.3.4. Spain

8.3.5. UK

8.3.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

8.5.3. Latin America

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Nano BiotechnologyMarket

9.5. Competitive Benchmarking

9.6. Leading Players in terms of Number of Developments in the Global Nano BiotechnologyMarket

9.7. Key developments and Growth Strategies

9.7.1. New ProductLaunch/Service Deployment

9.7.2. Mergers&Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2020

9.8.2. Major Players R&D Expenditure, 2020

10. COMPANY PROFILES

10.1. Ablynx

10.1.1. Company Overview

10.1.2. Products Offered

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Nami Therapeutics

10.2.1. Company Overview

10.2.2. Products Offered

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Celgene Corporation

10.3.1. Company Overview

10.3.2. Products Offered

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Nanophase Technologies Corporation

10.4.1. Company Overview

10.4.2. Products Offered

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Sigma-Aldrich

10.5.1. Company Overview

10.5.2. Products Offered

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. SkyePharma Pharmaceuticals

10.6.1. Company Overview

10.6.2. Products Offered

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Nano Bridging Molecules SA

10.7.1. Company Overview

10.7.2. Products Offered

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. XanTec bioanalytics GmbH

10.8.1. Company Overview

10.8.2. Products Offered

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Nanobiotix

10.9.1. Company Overview

10.9.2. Products Offered

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Dabur Pharma

10.10.1. Company Overview

10.10.2. Product Offered

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL NANO BIOTECHNOLOGYMARKET SYNOPSIS, 2022–2030

TABLE 2 GLOBAL NANO BIOTECHNOLOGYMARKET ESTIMATES &FORECAST, 2022–2030 (USD MILLION)

TABLE 3 GLOBAL NANO BIOTECHNOLOGYMARKET, BYAPPLICATION, 2022–2030 (USD MILLION)

TABLE 4 GLOBAL NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 5 NORTH AMERICA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 6 NORTH AMERICA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 7 US NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 8 US NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 9 CANADA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 10 CANADA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 11 EUROPE NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 12 EUROPE NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 13 GERMANY NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 14 GERMANY NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 15 UK NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 16 UK: NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 17 FRANCE NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 18 FRANCE NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 19 ITALY NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 20 ITALY NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 21 SPAIN NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 22 SPAIN NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 23 REST OFEUROPE NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 24 REST OFEUROPE NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 25 ASIA-PACIFICNANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 26 ASIA-PACIFIC NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 27 INDIA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 28 INDIA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 29 CHINA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 30 CHINA NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 31 JAPAN NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 32 JAPAN NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 33 SOUTH KOREA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 34 SOUTH KOREA BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 35 AUSTRALIA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 36 AUSTRALIA BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 37 REST OF ASIA-PACIFICNANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 38 REST OF ASIA-PACIFIC NANO BIOTECHNOLOGYMARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 39 REST OF THE WORLD NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 40 REST OF THE WORLD NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 41 MIDDLE EAST NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 42 MIDDLE EAST BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 43 AFRICA NANO BIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 44 AFRICA NANO BIOTECHNOLOGY MARKET, BY THERAPEUTICS, 2022–2030 (USD MILLION)

TABLE 45 LATIN AMERICABIOTECHNOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)

TABLE 46 LATIN AMERICANANO BIOTECHNOLOGYMARKET, THERAPEUTICS, 2022–2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL NANO BIOTECHNOLOGYMARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL NANO BIOTECHNOLOGYMARKET

FIGURE 4 GLOBAL NANO BIOTECHNOLOGY MARKET SHARE, BY APPLICATION, 2020 (%)

FIGURE 5 GLOBAL NANO BIOTECHNOLOGYMARKET SHARE, BY THERAPEUTICS, 2020 (%)

FIGURE 6 GLOBAL NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 EUROPE NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 ASIA-PACIFIC NANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 REST OF THE WORLDNANO BIOTECHNOLOGYMARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 GLOBAL NANO BIOTECHNOLOGYMARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 12 ABLYNX: KEY FINANCIALS

FIGURE 13 ABLYNX: SEGMENTAL REVENUE

FIGURE 14 ABLYNX: REGIONAL REVENUE

FIGURE 15 NAMI THERAPEUTICS: KEY FINANCIALS

FIGURE 16 NAMI THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 17 NAMI THERAPEUTICS: REGIONAL REVENUE

FIGURE 18 CELGENE CORPORATION: KEY FINANCIALS

FIGURE 19 CELGENE CORPORATION: SEGMENTAL REVENUE

FIGURE 20 CELGENE CORPORATION: REGIONAL REVENUE

FIGURE 21 NANOPHASE TECHNOLOGIES CORPORATION: KEY FINANCIALS

FIGURE 22 NANOPHASE TECHNOLOGIES CORPORATION: SEGMENTAL REVENUE

FIGURE 23 NANOPHASE TECHNOLOGIES CORPORATION: REGIONAL REVENUE

FIGURE 24 SIGMA-ALDRICH: KEY FINANCIALS

FIGURE 25 SIGMA-ALDRICH: SEGMENTAL REVENUE

FIGURE 26 SIGMA-ALDRICH: REGIONAL REVENUE

FIGURE 27 SKYEPHARMA PHARMACEUTICALS: KEY FINANCIALS

FIGURE 28 SKYEPHARMA PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 29 SKYEPHARMA PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 30 NANO BRIDGING MOLECULES SA: KEY FINANCIALS

FIGURE 31 NANO BRIDGING MOLECULES SA: SEGMENTAL REVENUE

FIGURE 32 NANO BRIDGING MOLECULES SA: REGIONAL REVENUE

FIGURE 33 XANTEC BIOANALYTICS GMBH: KEY FINANCIALS

FIGURE 34 XANTEC BIOANALYTICS GMBH: SEGMENTAL REVENUE

FIGURE 35 XANTEC BIOANALYTICS GMBH: REGIONAL REVENUE

FIGURE 36 NANOBIOTIX: KEY FINANCIALS

FIGURE 37 NANOBIOTIX: SEGMENTAL REVENUE

FIGURE 38 NANOBIOTIX: REGIONAL REVENUE

FIGURE 39 DABUR PHARMA: KEY FINANCIALS

FIGURE 40 DABUR PHARMA: SEGMENTAL REVENUE

FIGURE 41 DABUR PHARMA: REGIONAL REVENUE